Mechanisms of rejection: Role of complement

Current Opinion in Organ Transplantation

Volumn 19, Issue 1, 2014, Pages 8-13

  Farrar, Conrad A ^a   Sacks, Steven H ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

complement; rejection; transplantation

Indexed keywords

EID: 84895907581     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000037     Document Type: Review

References (47)

1. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11:785- 797.
2. Sacks SH, Zhou W. The role of complement in the early immune response to transplantation. Nat Rev Immunol 2012; 12:431-442.
3. Zhou W, Farrar CA, Abe K, et al. Predominant role for C5b-9 in renal ischemia/ reperfusion injury. J Clin Invest 2000; 105:1363-1371.
4. Farrar CA, Zhou W, Lin T, Sacks SH. Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J 2006; 20:217- 226.
5. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002; 8:582-587.
6. Peng Q, Li K, Smyth LA, et al. C3a and C5a promote renal ischemiareperfusion injury. J Am Soc Nephrol 2012; 23:1474-1485.
7. de Vries B, Kohl J, Leclercq WK, et al. Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol 2003; 170:3883-3889.
8. Lewis AG, Kohl G, Ma Q, et al. Pharmacological targeting of C5a receptors during organ preservation improves kidney graft survival. Clin Exp Immunol 2008; 153:117-126.
9. Farrar CA, Asgari E, Schwaeble WJ, Sacks SH. Which pathways trigger the role of complement in ischaemia/reperfusion injury? Front Immunol 2012; 3:341.
10. Schwaeble WJ, Lynch NJ, Clark JE, et al. Targeting of mannan-binding lectinassociated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc Natl Acad Sci U S A 2011; 108:7523-7528.
11. Farrar CA, Asgari E, Lynch N, et al. Mannan binding lectin associated serine protease-2 (MASP-2) is a critical player in the pathophysiology of renal ischaemia reperfusion (I/R) injury and mediates tissue injury in absence of complement C4. Mol Immunol 2009; 46:2832.
12. .van der Pol P, Schlagwein N, van Gijlswijk DJ, et al. Mannan-binding lectin mediates renal ischemia/reperfusion injury independent of complement activation. Am J Transplant 2012; 12:877-887.
13. Zhang M, Austen WG Jr, Chiu I, et al. Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc Natl Acad Sci U S A 2004; 101:3886-3891.
14. Zhang M, Alicot EM, Chiu I, et al. Identification of the target self-Antigens in reperfusion injury. J Exp Med 2006; 203:141-152.
15. Shi T, Moulton VR, Lapchak PH, et al. Ischemia-mediated aggregation of the actin cytoskeleton is one of the major initial events resulting in ischemiareperfusion injury. Am J Physiol Gastrointest Liver Physiol 2009; 296:G339- G347.
16. Bongoni AK, Kiermeir D, Jenni H, et al. Activation of the lectin pathway of complement in pig-to-human xenotransplantation models. Transplantation 2013; 96:791-799.
17. Damman J, Nijboer WN, Schuurs TA, et al. Local renal complement C3 induction by donor brain death is associated with reduced renal allograft function after transplantation. Nephrol Dial Transplant 2011; 26:2345-2354.
18. Berger SP, Roos A, Mallat MJ, et al. Low pretransplantation mannose-binding lectin levels predict superior patient and graft survival after simultaneous pancreas-kidney transplantation. J Am Soc Nephrol 2007; 18:2416-2422.
19. Bay JT, Sorensen SS, Hansen JM, et al. Low mannose-binding lectin serum levels are associated with reduced kidney graft survival. Kidney Int 2013; 83:264-271.
20. Damman J, Kok JL, Snieder H, et al. Lectin complement pathway gene profile of the donor and recipient does not influence graft outcome after kidney transplantation. Mol Immunol 2012; 50:1-8.
21. Damman J, Seelen MA. Mannan binding lectin: a two-faced regulator of renal allograft injury? Kidney Int 2013; 83:191-193.
22. Bay JT, Hein E, Sorensen SS, et al. Pretransplant levels of ficolin-3 are associated with kidney graft survival. Clin Immunol 2013; 146:240-247.
23. Peng Q, Li K, Anderson K, et al. Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a- C3aR interaction. Blood 2008; 111:2452-2461.
24. Peng Q, Li K, Wang N, et al. Dendritic cell function in allostimulation is modulated by C5aR signaling. J Immunol 2009; 183:6058-6068.
25. Li Q, Peng Q, Xing G, et al. Deficiency of C5aR prolongs renal allograft survival. J Am Soc Nephrol 2010; 21:1344-1353.
26. Li K, Fazekasova H, Wang N, et al. Functional modulation of human monocytes derived DCs by anaphylatoxins C3a and C5a. Immunobiology 2012; 217:65-73.
27. van Werkhoven MB, Damman J, van Dijk MC, et al. Complement mediated renal inflammation induced by donor brain death: role of renal C5a-C5aR interaction. Am J Transplant 2013; 13:875-882.
28. Peng Q, Li K, Patel H, et al. Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. J Immunol 2006; 176:3330-3341.
29. Lalli PN, Strainic MG, Yang M, et al. Locally produced C5a binds to T cellexpressed C5aR to enhance effector T-cell expansion by limiting antigeninduced apoptosis. Blood 2008; 112:1759-1766.
30. Li K, Patel H, Farrar CA, et al. Complement activation regulates the capacity of proximal tubular epithelial cell to stimulate alloreactive T cell response. J Am Soc Nephrol 2004; 15:2414-2422.
31. Vieyra M, Leisman S, Raedler H, et al. Complement regulates CD4 T-cell help to CD8 T cells required for murine allograft rejection. Am J Pathol 2011; 179:766-774.
32. Cravedi P, Leventhal J, Lakhani P, et al. Immune cell-derived C3a and C5a costimulate human T cell alloimmunity. Am J Transplant 2013; 13:2530-2539.
33. Strainic MG, Liu J, Huang D, et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4 T cells. Immunity 2008; 28:425-435.
34. Kwan WH, van der Touw W, Paz-Artal E, et al. Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells. J Exp Med 2013; 210:257-268.
35. Kendal AR, Chen Y, Regateiro FS, et al. Sustained suppression by Foxp3regulatory T cells is vital for infectious transplantation tolerance. J Exp Med 2011; 208:2043-2053.
36. van der Touw W, Cravedi P, Kwan WH, et al. Cutting edge: receptors for C3a and C5a modulate stability of alloantigen-reactive induced regulatory T cells. J Immunol 2013; 190:5921-5925.
37. Ma Q, Li D, Nurieva R, et al. Reduced graft-versus-host disease in C3- deficient mice is associated with decreased donor Th1/Th17 differentiation. Biol Blood Marrow Transplant 2012; 18:1174-1181.
38. Torok K, Kremlitzka M, Sandor N, et al. Human T cell derived, cell-bound complement iC3b is integrally involved in T cell activation. Immunol Lett 2012; 143:131-136.
39. .Dunkelberger J, Zhou L, Miwa T, Song WC. C5aR expression in a novel GFP reporter gene knockin mouse: implications for the mechanism of action of C5aR signaling in T cell immunity. J Immunol 2012; 188:4032-4042.
40. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-Allograft survival. N Engl J Med 2013; 369:1215- 1226.
41. Mengel M, Sis B, Haas M, et al. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012; 12:563-570.
42. Fuquay R, Renner B, Kulik L, et al. Renal ischemia-reperfusion injury amplifies the humoral immune response. J Am Soc Nephrol 2013; 24:1063- 1072.
43. Kohei N, Hirai T, Omoto K, et al. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012; 12:469-476.
44. Becker LE, Susal C, Morath C. Kidney transplantation across HLA and ABO antibody barriers. Curr Opin Organ Transplant 2013; 18:445-454.
45. Barnett AN, Asgari E, Chowdhury P, et al. The use of eculizumab in renal transplantation. Clin Transplant 2013; 27:E216-E229.
46. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11:2405-2413.
47. Sacks S, Karegli J, Farrar CA, et al. Targeting complement at the time of transplantation. Adv Exp Med Biol 2013; 735:247-255.